针对癌症治疗的模式识别受体:机制和策略
Dengjie Ouyang1,2,3, Ruixian Chen1,2, Haitong Xie1,2
1Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Acta pharmaceutica Sinica. B
|November 28, 2025
概括
模式识别受体 (PRR) 是癌症中的关键免疫传感器. 向PRR提供了一种有希望的策略,通过调节瘤微环境来增强癌症免疫疗法并克服治疗耐药性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 模式识别受体 (PRR) 对于检测微生物和宿主信号,启动免疫反应至关重要.
- PRRs包括托尔类受体 (TLR),RIG-I类受体,NOD类受体,C型莱克受体和细胞质DNA传感器.
- 这些受体对于调节炎症和瘤免疫力至关重要.
研究的目的:
- 审查PRRs在癌症进展和免疫逃避中的分子机制.
- 突出PRR向癌症治疗的最新进展.
- 探索基于PRR的策略与当前免疫疗法的整合.
主要方法:
- 文献综述专注于分子机制.
- 对最近关于PRR在癌症中的作用的研究进行分析.
- 对针对PRR的药物,特别是TLR激动剂的临床研究进行审查.
主要成果:
- PRRs在癌症中表现出双重作用,可能抑制或促进瘤生长.
- PRRs影响瘤微环境和免疫细胞激活.
- 准PRR可以增强对免疫疗法的反应,克服抗药性.
结论:
- PRRs是免疫和癌症之间的相互作用的重要调节者.
- 针对PRRs,特别是TLR激动剂的治疗向显示出增强抗瘤免疫力的前景.
- 基于PRR的疗法正在研究,以提高现有的癌症免疫疗法的疗效,包括免疫检查点抑制剂.
关键词:
C型莱克受体是C型莱克受体.癌症 癌症 癌症 癌症细胞质DNA传感器 细胞质DNA传感器免疫治疗是一种免疫疗法.类似NOD的受体模式识别受体是一种模式识别受体.像RIG-I一样的受体收费类受体的收费类受体更多相关视频
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
54.0K
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
4.3K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
